| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
In order to determine a new treatment option for type 2 diabetes mellitus, this study focused on the macrophage erythroblast attacher (MAEA), a type 2 diabetes mellitus susceptibility gene identified via genome-wide association study (GWAS). MAEA encodes a protein involved in the terminal maturation and enucleation of erythroid cells; however, no association with type 2 diabetes mellitus has been reported and clarification of its functions is still awaited. Therefore, to investigate its effect on type 2 diabetes mellitus, MAEA was highly expressed in mouse and mouse primary hepatocytes using a novel adenovirus vector suitable as a gene therapy vector for metabolic diseases. Expression of the gluconeogenesis gene was suppressed by highly expressing MAEA. The results suggest that MAEA may lead to a new type of treatment for type 2 diabetes mellitus by suppressing gluconeogenesis.
|
